Smoking Cessation Market Fired up with the Introduction of Chantix

Business Wire, Feb 25, 2008

PALO ALTO, Calif. -- The United States has gradually woken up to the high health hazards of smoking, with approximately 75 percent of the smokers in the country wishing to quit smoking. Realizing that it has the most easily avoidable reason for mortality, city and state governments have passed numerous anti-smoking laws. This, along with the introduction of Chantix, the first smoking cessation drug in almost a decade, has given a huge boost to the smoking cessation medication market.

New analysis from Frost & Sullivan (http://www.pharma.frost.com), U.S. Smoking Cessation Market, finds that the market earned revenues of $111.5 million in 2006 and estimates this to reach $1,532.6 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the U.S. Smoking Cessation Market, then send an e-mail to Melina Trevino, Corporate Communications, at mtrevino_pr@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you via e-mail.

The rising population of smokers in the United States has increased concerns about health risks to both smokers and passive smokers, thus creating a vast market for effective smoking cessation therapies. The 2006 launch of Chantix, the revolutionary smoking cessation drug, has reversed the fortunes of this market by reviving end-user interest in it.

Chantix is touted as the first blockbuster drug in this market and is expected to generate millions in revenue and expand the market at a remarkable rate. Additionally, Chantix offers an innovative and free support program called GETQUIT for buyers of this product. This type of innovation has not only increased the utilization of smoking cessation products but also inspired companies to include treatments that address the psychological aspects of smoking.

Improvements in the efficacy of smoking cessation medications will greatly help improve patient compliance and encourage further drug development. Currently, the U.S. market has only two approved medications for smoking cessation.

"With the increasing cost of drug and vaccine development, it is becoming more difficult for smaller companies to have the ability to develop products that make it through the approval process," says Frost & Sullivan Research Analyst Katheryn Symank. "These companies need to partner with larger companies that have more resources to further develop pipeline compounds."

The imminent launch of two new drugs in 2012 and 2013 and novel approaches to the treatment of smoking expect to buoy the market. Further, scientists are developing vaccines to address the addiction to nicotine, which can revolutionize the approach to smoking cessation.

Market participants can also take heart from the waning popularity of smoking in the United States. This trend has manifested in the increasing number of anti-smoking laws adopted by states and cities. These laws prohibit smoking in private workplaces, restaurants, and bars.

"All 50 states and the District of Columbia have passed laws that restrict smoking to certain places," notes Symank. "Fueling some of these restrictions is the finding that there is no safe level of exposure to secondhand smoke and that the only way to protect nonsmokers is to entirely prohibit smoking in enclosed spaces."

By July 2007, 15 states had implemented strict laws, while several others started to follow suit. In fact, another seven states have implemented similar laws and will put them into effect in 2008. Due to these numerous restricting laws, smokers have found it difficult to light up in public. This constraint is likely to go a long way in raising demand for smoking cessation drugs.

U.S. Smoking Cessation Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service program, which also includes research in the following markets: U.S. multiple sclerosis markets, U.S. asthma/COPD market, U.S. COPD market - therapeutic overview and patient outlook. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

U.S. Smoking Cessation Market

N2DE